Treatment of Hepatitis C in Patients Infected with Human Immunodeficiency Virus in the Direct-Acting Antiviral Era

Infectious Disease Clinics of North America

Volumn 26, Issue 4, 2012, Pages 931-948

  Soriano, Vincent ^a   Labarga, Pablo ^a   Vispo, Eugenia ^a   Fernández Montero, José Vicente ^a   Barreiro, Pablo ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Boceprevir; Coinfection; Direct acting antivirals; Drug interactions; Drug resistance; Hepatitis C; HIV; Telaprevir

Indexed keywords

ABACAVIR; ALPHA INTERFERON; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; ATORVASTATIN; BOCEPREVIR; DANOPREVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ESCITALOPRAM; ESOMEPRAZOLE; FOSAMPRENAVIR PLUS RITONAVIR; KETOCONAZOLE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MERICITABINE; METHADONE; MIDAZOLAM; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; STAVUDINE; TELAPREVIR; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; N (3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL) 3 (2 ((((1,1 DIMETHYLETHYL)AMINO)CARBONYL)AMINO) 3,3 DIMETHYL 1 OXOBUTYL) 6,6 DIMETHYL 3 AZABICYCLO(3.1.0)HEXAN 2 CARBOXAMIDE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE;

ANEMIA; CROSS RESISTANCE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIVER FIBROSIS; LIVER TRANSPLANTATION; MIXED INFECTION; MONOTHERAPY; NAUSEA; NONHUMAN; PHENOTYPE; PREVALENCE; PRURITUS; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS REPLICATION; VOMITING; ANTIVIRAL RESISTANCE; ARTICLE; ISOLATION AND PURIFICATION; VIROLOGY;

ANTIVIRAL AGENTS; COINFECTION; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; OLIGOPEPTIDES; PROLINE;

EID: 84867682175     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2012.08.004     Document Type: Review

References (62)

1. Weber R., Sabin C., Friis-Møller N., et al. Liver-related deaths in persons infected with the HIV: the D: A:D study. Arch Intern Med 2006, 166:1632-1641.
2. Ruppik M, Ledergerber B, Rickenbach M, et al. Changing patterns of causes of death: SCCS, 2005 to 2009. Presented at CROI, Boston (MA), February 27-March 2, 2011 [abstract 789].
3. Merwat S., Vierling J. HIV infection and the liver: the importance of HCV-HIV coinfection and drug-induced liver injury. Clin Liver Dis 2011, 15:131-152.
4. Peters M., Soriano V. HIV and the liver. Sherlock's diseases of the liver and biliary system 2011, 438-451. Blackwell Publishing Ltd, Oxford (United Kingdom). 12th edition. J. Dooley, A. Lok, A. Burroughs (Eds.).
5. Soriano V., Puoti M., Sulkowski M., et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007, 21:1073-1089.
6. European AIDS Clinical Society (EACS) guidelines, October 2011. Available at: Accessed August 28, 2012. http://www.europeanaidsclinicalsociety.org.
7. Qurishi N., Kreuzberg C., Luchters G., et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003, 362:1708-1713.
8. Shafran S. Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2007, 44:551-556.
9. Blanco F., Barreiro P., Ryan P., et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011, 18:11-16.
10. Soriano V., Puoti M., Garcia-Gascó P., et al. Antiretroviral drugs and liver injury. AIDS 2008, 22:1-13.
11. Nuñez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010, 52:1143-1155.
12. Labarga P., Soriano V., Vispo M.E., et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007, 196:670-676.
13. Dore G., Torriani F., Rodriguez-Torres M., et al. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection. AIDS 2007, 21:1555-1559.
14. Medrano J., Resino S., Vispo E., et al. HCV treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. J Viral Hepat 2011, 18:325-330.
15. Poveda E., Vispo E., Barreiro P., et al. Predicted effect of direct acting antivirals in the current HIV-HCV coinfected population in Spain. Antivir Ther 2012, 17:571-575.
16. Maida I., Núñez M., González-Lahoz J., et al. Liver transplantation in HIV-HCV coinfected candidates: what is the most appropriate time for evaluation?. AIDS Res Hum Retroviruses 2005, 21:599-601.
17. Tan-Tam C., Frassetto L., Stock P. Liver and kidney transplantation in HIV-infected patients. AIDS Rev 2009, 11:190-204.
18. Jacobson I., McHutchison J., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
19. Hezode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839-1850.
20. McHutchison J., Manns M., Muir A., et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010, 362:1292-1303.
21. Marcellin P., Forns X., Goeser T., et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or 2b to patients with chronic hepatitis C. Gastroenterology 2011, 140:459-468.
22. Poordad F., McCone J., Bacon B., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
23. Bacon B., Gordon S., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
24. Lenz O, Fevery B, Vijgen L, et al. TMC-435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon/ribavirin treatment: virological analyses of the ASPIRE trial. Presented at 47th EASL, Barcelona, April 18-22, 2012 [abstract 9].
25. Chu T., Kulkarni R., Gane E., et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 2012, 142:790-795.
26. Seden K., Back D., Shoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother 2010, 65:1079-1085.
27. Jiménez-Nácher I., Alvarez E., Morello J., et al. Approaches for understanding and predicting drug interactions in HIV-infected patients. Expert Opin Drug Metab Toxicol 2011, 7:457-477.
28. Soriano V., Sherman K., Rockstroh J., et al. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. AIDS 2011, 25:2197-2208.
29. Rallón N., Naggie S., Benito J.M., et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010, 24:F23-F29.
30. Nattermann J., Vogel M., Nischalke H., et al. Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C. J Infect Dis 2011, 203:595-601.
31. Ryan P., Berenguer J., Michelaud D., et al. Insulin resistance is associated with advanced liver fibrosis and high body mass index in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2009, 50:109-110.
32. Cacoub P., Carrat F., Bedossa P., et al. Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study. Antivir Ther 2009, 14:839-845.
33. Dieterich D, Soriano V, Sherman K, et al. Telaprevir in combination with peginterferon α-2a plus ribavirin for HIV/HCV coinfected patients: SVR12 interim analysis. Presented at 19th CROI. Seattle (WA), March 5-8, 2012 [abstract 56].
34. Mallolas J, Pol S, Rivero A, et al. Boceprevir plus peginterferon/ribavirin for the treatment of HIV-HCV coinfected patients: end of treatment week 48 interim results. Presented at 47th EASL Barcelona, April 18-22, 2012 [abstract 366].
35. Soriano V., Perelson A., Zoulim F. Why different dynamics of selection of drug resistance in HIV, hepatitis B and C viruses?. J Antimicrob Chemother 2008, 62:1-4.
36. Morsica G., Bagaglio S., Uberti-Foppa C., et al. Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2009, 51:106-108.
37. Plaza Z., Soriano V., González M.M., et al. Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV-HCV coinfected patients. J Antimicrob Chemother 2011, 66:2838-2842.
38. Soriano V., Vispo E., Labarga P., et al. Viral hepatitis and HIV co-infection. Antiviral Res 2010, 85:303-315.
39. Lafeuillade A., Hittinger G., Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001, 357:280-281.
40. Mauss S., Valenti W., De Pamphilis J., et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004, 38:F21-F25.
41. Garcia-Benayas T., Blanco F., Soriano V. Weight loss in HIV-infected patients. N Engl J Med 2002, 347:1287-1288.
42. Fleischer R., Boxwell D., Sherman K. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis 2004, 38:e79-e80.
43. Vispo E., Barreiro P., Pineda J.A., et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008, 13:429-437.
44. Mira J.A., López-Cortés L., Barreiro P., et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008, 62:1365-1373.
45. Rodríguez-Nóvoa S., Morello J., González M., et al. Increase in serum bilirubin in HIV/hepatitis C virus-coinfected patients on atazanavir therapy following initiation of pegylated interferon and ribavirin. AIDS 2008, 22:2535-2537.
46. Van Heeswijk R, Vandervoorde A, Boogaerts G, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. Presented at 18th CROI. Boston (MA), February 27-March 2, 2011 [abstract 119].
47. Van Heeswijk R, Gysen V, Boogaerts G, et al. The pharmacokinetic interaction between tenofovir disoproxil fumarate and the investigational HCV protease inhibitor telaprevir. Presented at 48th ICAAC. Washington (DC), October 25-28, 2008. p. A-966.
48. Van Heeswijk R, Boogaerts G, de Paepe E, et al. The pharmacokinetic interaction between escitalopram or esomeprazole and telaprevir. Presented at 15th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Boston (MA), June 23-24, 2010 [abstract 76].
49. Van Heeswijk R., Vandevoorde A., Verboven P., et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir. EASL, Berlin, Germany; March 30-April 3, 2011. J Hepatol 2011, 54(Suppl):491-492. [abstract 1244].
50. Ghosal A., Yuan Y., Tong W., et al. Characterisation of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 2011, 39:510-521.
51. Kasserra C, Hughes E, Treitel M, et al. Clinical pharmacology of BOC: metabolism, excretion and drug-drug interactions. Presented at 18th CROI. Boston (MA), February 27-March 2, 2011 [abstract 118].
52. Rong L., Dahari H., Ribeiro R., et al. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010, 2:30-32.
53. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010, 138:447-462.
54. Guedj J., Perelson A. Second-phase HCV RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 2011, 53:1801-1808.
55. Halfon P., Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011, 55:192-206.
56. Soriano V., Vispo E., Poveda E., et al. Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother 2011, 66:1673-1686.
57. Kieffer T., Kwong A., Picchio G. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010, 65:202-212.
58. Treviño A., de Mendoza C., Parra P., et al. Natural polymorphisms associated with resistance to new antivirals against hepatitis C virus (HCV) in newly diagnosed HIV/HCV-coinfected patients in Spain. Antivir Ther 2011, 16:413-416.
59. Trimoulet P., Belzunce C., Faure M., et al. HCV protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients. HIV Med 2011, 12:506-509.
60. Miro JM, Castells L, Valdivieso A, et al. Treatment with pegIFN+RBV of 67 HIV+ patients with recurrent HCV infection after liver transplantation. Presented at CROI 2011. Boston (MA), February 27-March 2, 2011 [abstract 964].
61. Garg V., van Heeswiijk R., Eun-Lee J., et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011, 54:20-27.
62. Soriano V. A new era for hepatitis C - new diagnostic tools and new weapons. ACS Med Chem Lett, in press.